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Figure 1
Comparison of our results to previous studies.
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Figure 2
Distribution of explants.
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An intrathecal delivery system allows direct
infusion of analgesics and antispasmodic
drugs into the cerebral spinal fluid in patients
with chronic intractable pain or spasticity.
Intrathecal therapy effective but any surgical
intervention carries the risk of complications.
Complications encountered with this therapy
include wound dehiscence (spontaneous
reopening) and infection, which often lead
to explanation of the intrathecal pump. Later
re-implanation is feasible, but there is limited
information regarding successful retention of
the device after re-implantation. A recurring
problem with generating reliable guidelines
in neurosurgery is that some situations occur
too rarely for evidence to be much more than
anecdotal.
We wanted to establish a protocol for patient
selection for re-implantation prior to surgery,
using data acquired at our own institution.
Between 2001 and 2009, a total of 219 implant
procedures, including revisions, were performed
in 175 patients. Of these, 12 patients had their
intrathecal system explanted. Comparing our
results to pooled data from prior publications
(Figure 1), we have a lower infection rate and a
higher re-implantation rate.
Figure 2 shows the breakdown of explants and
re-implantations. 8/12 explants were secondary
to an infection and/or wound dehiscence. Seven
of the explanted patients were subsequently
re-implanted. The average period between
explantation and re-implantation was 13
months (range 1-26 months) and re-implanted
patients were followed up for a mean period of
26 months (range 4-51 months).
No specific co-morbidity was predictive
of explantation. Of the seven re-implanted
patients, six had a single episode of infection
or dehiscence leading to explantation and
one had three episodes of either dehiscence
or infection leading to multiple explantations
and re-implantations. The multiple complications experienced by that single patient were
attributed to a congenital connective tissue
and lymphatic system disorder which created
a special challenge for wound healing. Three
patients, including the patient with multiple reimplantations, had their system explanted secondary to infection at the pump site with noted
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Figure 3
A. Preoperative (explantation) anterior-posterior view X-ray,
demonstrates primary intrathecal pump in the right lower
abdominal quadrant. B. Postoperative (re-implantation) anteriorposterior view X-ray, demonstrates newly re-implanted intrathecal
pump in the left lower abdominal quadrant.

symptoms of erythema, edema, drainage and
tenderness; two were explanted for incisional
dehiscence without clinical sign of infection;
and two patients had incisional dehiscence
along with clinical signs of infection.
In all seven, the pump re-implantations took
place with no complications, including no
recurrence of infections, pump contamination
or incisional dehiscence. Since our practice
represents a small sample, conclusions are
difficult to generalize. Re-implantation was
performed at a new/distant site (opposite side
of the abdomen or buttocks). An example is
shown in Figure 3. All explanted systems were
replaced by new intrathecal pumps during
re-implantation. All re-implanted intrathecal
systems were functioning at optimal levels,
providing adequate symptomatic relief.
Similarities were found among the seven
re-implanted patients, which may explain
how they have successfully retained their re-
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implanted devices without additional infection
or dehiscence. All patients completed a course
of antibiotics and remained infection-free
prior to re-implantation. All patients lived in a
private family dwelling, and were therefore at a
lower risk for exposure to iatrogenic infections.
All patients had access to assistance in the home
if needed for activities of daily living (ADLs),
including repositioning (for example, getting
into and out of bed) and mobility around the
house, and instrumental activities of daily living (IADLs) which include light housework,
preparing meals, and shopping for groceries
or clothes. All patients had convenient access
to health care providers. Only one of the seven
patients used tobacco. Six of the seven patients
were noted to have adequate nutritional status.
Using this data, a protocol can be created
to ensure the success of future patients who
require explanation of their baclofen pump due
to dehiscence or infection:

• Have patients completed a course of
antibiotics and remained infection free after
a period of time off all antibiotics?
• Have serum infection and nutrition
markers been measured at set point
intervals?
• Has the patient ceased all tobacco products?
• Is there support or assistance for
ADLs/IADLs, including mobility and
repositioning?
Further, a more systematic approach to patient
education during the time between explantation and re-implantation should be instituted.
At our institution, family members were
counseled meticulously on the importance for
strict compliance with post-operative follow up
schedule.
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